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ABSTRACT
Plastin 3 (PLS3), encoded by PLS3, is a newly recognized regulator of bone metabolism, and mutations in the encoding gene result in
severe childhood-onset osteoporosis. Because it is an X chromosomal gene, PLS3mutation-positive males are typically more severely
affectedwhereas females portray normal to increased skeletal fragility. Despite the severe skeletal pathology, conventionalmetabolic
bone markers tend to be normal and are thus insufficient for diagnosing or monitoring patients. Our study aimed to explore serum
microRNA (miRNA) concentrations in subjects with defective PLS3 function to identify novel markers that could differentiate subjects
according to mutation status and give insight into the molecular mechanisms by which PLS3 regulates skeletal health. We analyzed
fasting serum samples for a custom-designed panel comprising 192 miRNAs in 15 mutation-positive (five males, age range
8–76 years, median 41 years) and 14mutation-negative (six males, age range 8–69 years, median 40 years) subjects from four Finnish
families with different PLS3mutations. We identified a unique miRNA expression profile in the mutation-positive subjects with seven
significantly upregulated or downregulated miRNAs (miR-93-3p, miR-532-3p, miR-133a-3p, miR-301b-3p, miR-181c-5p, miR-203a-3p,
and miR-590-3p; p values, range .004–.044). Surprisingly, gender subgroup analysis revealed the difference to be even more distinct
in female mutation-positive subjects (congruent p values, range .007–.086) than in males (p values, range .127–.843) in comparison to
corresponding mutation-negative subjects. Although the seven identified miRNAs have all been linked to bone metabolism and two
of them (miR-181c-5p and miR-203a-3p) have bioinformatically predicted targets in the PLS3 30 untranslated region (30-UTR), none
have previously been reported to associate with PLS3. Our results indicate that PLS3mutations are reflected in altered serum miRNA
levels and suggest there is crosstalk between PLS3 and these miRNAs in bone metabolism. These provide new understanding of the
pathomechanisms by which mutations in PLS3 lead to skeletal disease and may provide novel avenues for exploring miRNAs as bio-
markers in PLS3 osteoporosis or as target molecules in future therapeutic applications. © 2020 The Authors. Journal of Bone and Min-
eral Research published by American Society for Bone and Mineral Research.
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Introduction
I n recent years, large-scale sequencing efforts and advancednext-generation sequencingmethods have enabled recognition
of several genetic factors and loci that associate with bone quality
and fracture risk and contribute to various skeletal pathologies.(1–5)
Nevertheless, understanding the complexities of the human
genome has proven difficult. Today, non-protein–coding genomic
components are considered to have an important, disease-
modulating role.(6–8) As such, microRNAs (miRNAs)—short, non-
coding RNA fragments—play an integral role in various biological
processes by regulating gene expression and protein translation
by posttranscriptional silencing or repression.(9) In bone, miRNAs
affect osteogenic cell maturation and function directly, and thus
partake in fetal skeletal development and maintenance of postna-
tal bone health.(10–12)miRNAs are also clinically valued because dif-
ferences in serum miRNA levels correlate with disease status and
mirror disease progression, differentiate between patient cohorts,
and will, possibly, offer newmeans of target treatments in the near
future.(8,13–15) We have previously reported altered miRNA concen-
trations in a monogenic skeletal disorder, WNT1 osteoporosis, and
shown that a uniquemiRNA pattern differentiates patients accord-
ing to their mutation status.(8) However, the significance and value
of miRNAs in other rare, monogenic bone diseases is still incom-
pletely explored.
Plastin 3, encoded by X chromosomally inherited PLS3, is a
newly recognized regulator of bone metabolism. In 2013, loss-
of-function mutations in PLS3 were identified as the cause for
severe childhood-onset, X-linked primary osteoporosis.(16) Hemi-
zygous males are commonly more severely affected and sustain
multiple low-energy peripheral and vertebral compression
fractures starting at an early age.(17–20) The phenotype in hetero-
zygous females varies from normal to increased skeletal
fragility.(17–20) Bone biopsies portray low turnover osteoporosis
with scarce bone cells, decreased bone formation, and heterog-
enous and defective matrix mineralization.(17,19) Although, to
date, many other patients and families worldwide have been
identified with PLS3 mutations and patients’ clinical skeletal
characteristics are well documented,(21) the main molecular
mechanisms and pathways through which PLS3 regulates and
diverges with in bone metabolism remain elusive.
To date, we have identified altogether four unrelated Finnish
families with PLS3 osteoporosis caused by different PLS3
mutations.(18–20) We and others have previously reported that
despite the manifest bone pathology, conventional metabolic
bone markers are normal in PLS3 mutation-positive patients
and hence offer no aid in clinical diagnosis or follow-up.(19) We
hypothesized that abnormal PLS3 function due to PLS3 muta-
tions is reflected in serummiRNA expression levels and therefore
set out to evaluate affected patients’ serum miRNA expression
profiles with the objective to distinguish probable new bio-
markers and shed light on the molecular pathomechanisms in
PLS3-related skeletal disorders.
Subjects and Methods
Subjects
We have previously identified four Finnish families with X-linked
PLS3 osteoporosis due to different mutations in PLS3
(Fig. 1).(18–20) The first family (Family A) has an intronic splice site
mutation c.73–24T>A (p.Asp25Alafs*17) identified by exome
Fig 1 Pedigrees of the four included Finnish families with PLS3mutations. Family A: intronic splice-site mutation c.73–24T>A (p.Asp25Alafs*17); Family B:
intragenic tandem duplication within PLS3; Family C: de novo heterozygous missense mutation c.1424A>G (p.Asn446Ser); and Family D: nonsense muta-
tion c.766C>T (p.Arg256*). The pedigrees have been modified to ensure anonymity. Squares represent males, circles females. MN = mutation-negative;
MP = mutation-positive.
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sequencing as described.(19) The second family (Family B)
includes three subjects with an intragenic tandem duplication
within PLS3 as identified by genomic hybridization array (array-
CGH).(20) The third family (Family C) consists of a single subject
with a de novo heterozygous missense mutation c.1424A>G (p.
Asn446Ser) in exon 12 identified by Sanger sequencing of the
whole PLS3 gene as described.(18) Last, the fourth family (Family
D) includes two subjects with a nonsense mutation c.766C>T
(p.Arg256*) in exon 8, also identified by conventional Sanger
sequencing of the whole PLS3 gene.(18)
Since initial recognition of each family’s mutation, we have
offered genetic screening to all first-degree family members
and hence, to date, we have identified altogether 21 PLS3
mutation-positive individuals in these four families (Family A,
n = 15; Family B, n = 3; Family C, n = 1; and Family D, n = 2).
For the current study, we offered all mutation-positive individ-
uals (n = 20; one deceased) the opportunity to take part in a
study concerning new bone biomarkers in PLS3 osteoporosis.
To form a comparable control group with a similar genetic back-
ground as well as age and gender distribution, we also offered
participation to the mutation-negative individuals (n = 31) from
these four families. In total 15 mutation-positive and 17 muta-
tion-negative individuals consented. All subjects or their legal
guardians gave a written informed consent upon participation
in the study. The research protocol was approved by the
Research Ethics Board of Helsinki University Hospital.
Each participant completed a questionnaire concerning other
chronic illnesses, previous fractures, orthopedic surgeries, osteo-
porosis and other long-term medications, and calcium and vita-
min D supplementation. All anamnestic data were reviewed for
possible confounding factors regarding miRNA expression
levels.
Genetic evaluations
We have previously screened all participating individuals for
the families’ pertinent PLS3 mutations. Genetic validations were
performed on DNA extracted from peripheral blood as
described.(18–20)
Serum samples
We collected serum samples from all subjects during the sum-
mer months (June–August) in 2017 to avoid seasonal bias from
variable sunlight exposure. We collected all samples after an
overnight fast, in the morning between 8:00 a.m. and 9:00
a.m. First, we collected venous peripheral blood in normal serum
tubes, let them stand and clot at room temperature for
30–60 min, and then centrifuged them at 2500g for 10 min.
The supernatants were then transferred to 1.5-mL tubes in
250-μL aliquots and stored immediately at −80C until analysis.
Blood biochemistry
We have previously measured basic biochemistry and conven-
tional bone metabolic markers for each subject. These included
serum ionized calcium, phosphate, alkaline phosphatase (ALP),
and 25-hydroxyvitamin D (S-D-25) (assessed with immunochem-
iluminometry) at HUSLAB Laboratory (Helsinki, Finland). Parathy-
roid hormone (PTH) and bone resorption marker collagen type
1 cross-linked C-telopeptide (CTX-1) were both assessed from
serum with an IDS-iSYS fully automated immunoassay system
(Immunodiagnostic Systems, Ltd., Bolton, UK). For each parame-
ter, results were compared with the laboratory’s or
manufacturer’s reference values. All were measured from blood,
serum, or plasma samples collected in parallel with the samples
for the miRNA analyses.
miRNA analyses
Serum was thawed at room temperature and centrifuged at
room temperature for 5 min at 12,000g to remove cellular debris.
RNA extraction was performed using precisely 200 μL serum as
described(8,15) using the miRNeasy Mini Kit (Qiagen, Hilden, Ger-
many) with the following modification: synthetic, nonhuman oli-
gonucleotides (Qiagen) were added to the Qiazol lysis buffer,
glycogen was added to the precipitation at a final concentration
of 0.5 mg/mL to enhance precipitation, and columns were
washed three times with ethanol before elution in 30 μL
nuclease-free water. Eluted total RNA was stored at −80C until
further analysis.
Four microliters (4 μL) of total RNA were mixed with cel-miR-
39 (RT spike-in control; Qiagen) and used for reverse transcrip-
tion (RT) using the miRCURY RT kit (Qiagen) in 10-μL reactions
at 42C for 60 min. The resulting cDNA was overall diluted
1:100 for qPCR analysis using the 2× miRCURY SYBR Green mix
and nuclease-free water (Qiagen). qPCRs were performed in
10-μL reactions using custom designed 384-well plates with
dried miRCURY LNA primers (Qiagen) targeting 192 different
miRNAs and quality controls per sample. Forty-five qPCR cycles
were performed according to the manufacturer’s instructions
for two-step protocols optimized for Roche LC480 II instruments
(Roche Diagnostics, Mannheim, Germany). The resulting fluores-
cence data were used to derive cycle quantification (Cq) values
using the second derivative method. Cq values for RNA, RT,
and PCR spike-in controls were visually inspected to identify
samples where analysis had failed. Hemolysis was judged based
on the ratio between miR-23a-3p and miR-451a, according to
Blondal and colleagues.(22) Samples with high quality were
selected for further analysis, for which global mean normaliza-
tion was performed based on the average Cq signal, as calcu-
lated based on the signals from all detected (Cq < 40) miRNAs
per sample.
We screened all serum samples with a previously described
analytical workflow for 192 distinct miRNA species and con-
trols.(8,15) The primary outcomes of interest were the top 10%
of most differentially expressed miRNAs and the number and
type of significantly differentially expressed miRNAs specific to
subjects with PLS3 mutations. The specific miRNAs represent an
unbiased selection of the most abundant and measurable miR-
NAs in human serum or plasma.(8,15) We added spike-in controls
prior to RNA extraction, RT, and qPCR amplification to evaluate
possible technical variance of the workflow and to detect poten-
tial outliers. To exclude the possibility that results would be
biased by hemolysis, we calculated a hemolysis index from the
ratio of miR-451a and miR-23a-3p, as described by Blondal and
colleagues.(22) miRNA target prediction was performed using
TargetScan (v7.2) (https://lens.elifesciences.org/05005/index.
html) and miRWalk (v3.0)(23) using the default parameters. Gene
set enrichment analysis (GSEA) was performed using miRWalk
(v3.0) using the default parameters and intersection with Tar-
getScan prediction. Experimental design, protocols, and
raw and normalized RT-qPCR data have been submitted to NCBI
Gene Expression Omnibus (accession number GSE142872;
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1428
72) to enable public access to our dataset.
Journal of Bone and Mineral Researchn 1964 MÄKITIE ET AL.
In vitro luciferase 3’-UTR reporter assay
To confirm binding of miR-181c-5p and miR-203a-3p to the 3’-UTR
of PLS3, a dual luciferase reporter systemwas applied. The 3’-UTR of
human PLS3 (transcript variant 202, ENST00000355899.8) was
cloned into psiCHECK™-2 (Promega, San Luis Obispo, CA, USA).
HEK293 cells, cultivated in high-glucose Dulbecco’s Modified
Eagle’s Medium (Lonza, Basel, Switzerland) and supplemented
with 2mM L-Glutamine, 10% fetal calf serum (Sigma-Aldrich,
St. Louis, MO, USA), and 1% PenStrep (Sigma-Aldrich), were co-
transfected with psiCHECK2-PLS3-3’-UTR and either a miRNA
mimic hsa-181c-5p or hsa-203a-3p, or Negative Control #1
(mirVana™; Thermo Fisher Scientific, Waltham, MA, USA). Jet-
Prime transfection reagent (Polyplus Transfection, New York,
NY, USA) was used for transfections that were performed accord-
ing to the manufacturer’s protocol. Briefly, 0.25 μg/mL and
0.1 μg/mL plasmid DNA were mixed with the respective miRNA
(30nM final concentration), incubated for 15 min at room tem-
perature, and added to the cells. Medium was exchanged with
fresh growth medium after 24 hours. Luciferase assay was per-
formed 48 hours posttransfection using the Dual-Luciferase®
Reporter Assay System (Promega, Madison, WI, USA) according
to the manufacturer’s protocol. Luminescence was measured
on a Polarstar Omega (BMG Labtech, Ortenberg, Germany).
Renilla luciferase activity was normalized against Firefly lucifer-
ase activity.
Statistical analyses
Descriptive data are given as median and range when appropri-
ate. Statistical calculations are done by comparing both
mutation-positive with mutation-negative subjects and for each
gender group separately. Adjustment for other possible con-
founders was not reasonable due to small cohort size. We used
Kolmogorov–Smirnov and Shapiro–Wilk tests to evaluate nor-
mality of data. We used unpaired two-tailed Student’s t test
and Mann–Whitney, U test, as appropriate (SPSS Statistics 24;
IBM Corporation, Armonk, NY, USA). Values of p <.05 were con-
sidered statistically significant. miRNA volcano plots were drawn
using effect sizes (delta–delta-Cq values) and p values derived
from unpaired two-tailed Student’s t test. Principal components
analysis (PCA) and hierarchical clustering analysis were per-
formed using Clustvis,(24) using delta Cq (dCq) normalized data
as input values. Unit variance scaling was applied and the singu-
lar value decomposition (SVD) with imputation method, which is
available with the pcaMethods package (v1.78) in R/Bioconduc-
tor (https://www.bioconductor.org/), was used. We used Med-
Calc Statistical Software (version 18; MedCalc Software Ltd,
Ostend, Belgium; http://www.medcalc.org) to perform receiver
operator characteristic (ROC) curve analysis for individual miR-
NAs to compute the area under the ROC curve (AUC) values.
Pearson and Spearman correlation analyses and two-tailed tests
were performed in GraphPad Prism v8.3.0 (GraphPad Software,
Inc., La Jolla, CA, USA). Power calculations for cohort size were
not considered as all available PLS3 mutation-positive subjects
and their respective mutation-negative family members were
included in the study. One-way ANOVA analysis with Tukey’s
post hoc test was used for analysis of in vitro data. Values of
p obtained from miRWalk 3.0 target predictions were adjusted
for multiple testing using the Benjamini–Hochberg method for
false-discovery rate calculation.
Results
Cohort characteristics
Mutation-positive subjects
The current study cohort comprised in total 15 PLS3 mutation-
positive subjects (five males; age range, 8–76 years; median
age 41 years) (Fig. 1, Table 1). The subjects had a variable history
of previous peripheral (range, 0 to >10) and vertebral compres-
sion fractures. Two subjects had sustained a peripheral fracture
within the last 12 months prior to the study; to our knowledge
none resulted from high-energy trauma. None of the subjects
had undergone any orthopedic surgery within the last
12 months. Seven of the subjects had received prior osteoporo-
sis medication and for two subjects, the treatment was ongoing
at the time of the study; subject MP33 had received an infusion
of zoledronic acid at dose 0.05 mg/kg 11 months prior to obtain-
ing the samples, and subject MP23 had similarly received 5 mg
intravenous zoledronic acid 1 month prior to the sample collec-
tion (Table 1).
Mutation-negative subjects
The control group included 17mutation-negative subjects (eight
males; age range, 8–69 years; median 41 years) (Fig. 1, Table 1).
They also had a variable history of peripheral fractures (more
than two fractures only in one subject) and one subject had sus-
tained vertebral compression fractures; none of them reported
recent fractures or high-energy traumas. One subject (MN36)
had received prior osteoporosis medication and another subject
(MN21) was receiving denosumab-injections twice a year at the
time of the study. None of the subjects had had any orthopedic
surgery within the last 12 months.
Clinical and biochemical characteristics
Evaluation of basic parameters of calcium-phosphate homeosta-
sis and metabolic bone turnover markers showed generally nor-
mal findings and only isolated supra- or subnormal values in
both mutation-positive and -negative subjects (Supplemental
Fig. 1, Supplemental Table 1); no systematic differences were
noted in relation to the subjects’mutation status, age, or gender.
Serum vitamin D concentrations were similar in both groups
(medians 69 versus 73 nmol/L).
miRNA quantitation quality control
Overall, there was low technical variance and low variability in
data (coefficient of variation [CV]% <30) (Supplemental Fig. 2).
Hemolysis index calculations detected three samples (MN27,
MN29, and MN35) with ratios above a threshold of >7; they were
subsequently excluded from further analyses, leaving a total
number of 14mutation-negative subjects (consisting of sixmales
with new age median of 40 years). No samples from mutation-
positive subjects were excluded for low sample quality.
Exploratory data analysis
With regard to the X chromosomal inheritance of PLS3, we eval-
uated the gender-specific effect of the PLS3 mutations on the
mutation-positive subjects’ overall miRNA serum levels. We
selected the 10% (ie, 20 miRNAs altogether) most upregulated
or downregulated miRNAs (based on standard deviation) and
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Fig 2 Principal component analysis for the top 20 most regulated miRNAs according to p value in 15 PLS3mutation-positive and 14 mutation-negative
subjects. The figure shows gender-divide and grouping in the mutation-positive subjects (green versus purple), indicating gender difference in miRNA
expression in PLS3mutation-positive subjects and altered circulatingmiRNA levels particularly in female mutation-positive subjects. F = female, M =male,
PC = principal component.
Table 2 Differential Expression of the Top 20 Putative miRNAs in 15 PLS3Mutation-Positive Subjects and 14 Mutation-Negative Subjects
Average
normalized
delta Cq
Standard
deviation
(Cq value) p (t test)
miRNA-ID
Regulation in
MP subjects MP MN MP MN
Fold change (log2-
transformed)
Fold change (linear)
MP versus MN All Females Males
ROC analysis,
AUC value
miR-93-3p Down −1.49 −0.94 0.54 0.40 −0.55 0.68 .004 .007 .344 0.812
miR-532-3p Down −1.60 −1.14 0.47 0.29 −0.46 0.73 .007 .027 .206 0.819
miR-133a-3p Down −4.91 −3.47 1.50 0.85 −1.44 0.37 .009 .042 .127 0.795
miR-301b-3p Up −3.42 −4.19 0.86 0.91 0.77 1.71 .015 .017 .465 0.762
miR-181c-5p Up −4.75 −6.20 1.82 2.28 1.45 2.73 .032 .086 .246 0.690
miR-203a-3p Up −5.10 −7.12 2.58 2.49 2.02 4.06 .035 .064 .454 0.726
miR-590-3p Down −2.75 −2.34 0.54 0.30 −0.41 0.75 .039 .021 .843 0.707
miR-23b-3p Up 4.36 4.21 0.21 0.19 0.15 1.11 .064 .016 .682 –
miR-30c-5p Up 2.67 2.44 0.35 0.34 0.23 1.17 .078 .086 .663 –
miR-218-5p Up −5.70 −7.62 2.58 2.99 1.92 3.78 .083 .132 .463 –
miR-128-3p Up −0.91 −1.12 0.30 0.32 0.21 1.16 .084 .011 .428 –
miR-29b-3p Down 0.90 1.17 0.37 0.45 −0.27 0.83 .097 .020 .795 –
miR-31-5p Down −5.82 −4.76 1.79 1.41 −1.06 0.48 .099 .032 .712 –
miR-15b-5p Up 2.32 2.18 0.20 0.21 0.14 1.10 .100 – – –
miR-423–3p Up 1.92 1.73 0.29 0.28 0.19 1.14 .101 – – –
miR-96-5p Down −3.67 −2.23 2.95 0.88 −1.44 0.37 .103 – – –
miR-200b-3p Up −3.27 −3.85 0.87 0.99 0.58 1.49 .113 – – –
miR-582-3p Down −7.18 −5.71 2.46 2.19 −1.47 0.36 .114 – – –
miR-24-3p Up 5.37 5.22 0.20 0.27 0.15 1.11 .114 – – –
miR-141-3p Up −2.23 −2.71 0.74 0.83 0.48 1.39 .123 – – –
miRNAswith overall p value < 0.05 are shown in bold. Parametric t test used as appropriate. For clarity, yellow indicates p value < 0.05 and blue indicates
p value < 0.1.
AUC = area under the ROC curve; Cq = cycle quantification value; miRNA/miR = microRNA; MN = mutation-negative; MP = mutation-positive;
ROC = receiver operator characteristic.
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applied unsupervised exploratory data analyses by PCA. Princi-
pal components 1 and 2 together explained 36.3% of the overall
variance but were not sufficient for complete separation of
mutation-positive from mutation-negative subjects in the plot
(Fig. 2). Interestingly, mutation-negative male and female sub-
jects clustered together (Fig. 2, red versus blue), while in the
mutation-positive subjects grouping by gender was observed
(Fig. 2, green versus purple).
We next performed statistical analysis of the top 20 miRNA
concentrations using groupwise comparisons. Of these, alto-
gether 13miRNAs showed a p value <.1 and of them, seven puta-
tive miRNAs were identified with a p value <.05 and were hence
deemed discriminative for the mutation-positive and mutation-
negative subjects (Table 2). Heat map analysis for clustering of
these top 20 miRNAs showed no correlation with mutation type
or subfamily division (Supplemental Figs. 3 and 4). Calculations
for correlations between the top 20 miRNAs and subject age
revealed that two of the miRNAs had statistically significant cor-
relations: miR-29b-3p, p value .0393, and miR-141-3p, p value
.0044 (Supplemental Table 2); neither is included in the top
seven differentially expressed miRNAs.
We decided to concentrate on the top 13 miRNAs with lowest
p values <.1 (range, .004–.099) and evaluate them in more detail
(Table 2). Of these, three were statistically significantly upregu-
lated (miR-301b-3p, miR-181c-5p, and miR-203a-3p; p value
range, .015–.035), four were upregulated (miR-23b-3p, miR-30c-
Fig 3 (A–G) Box plots of normalized (global mean) delta Cq values for the top seven regulated miRNAs in 15 PLS3 mutation-positive and 14 mutation-
negative subjects. Individuals with ongoing osteoporosis medication at the time of the study are indicated with red dots. Asterisk (E,F) refers to compar-
ison between all MN and all MP subjects. Parametric t test was applied. F = female; M = male; MN = mutation-negative; MP = mutation-positive.
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5p, miR-218-5p, and miR-128-3p; p value range, .064–.084), four
were statistically significantly downregulated (miR-532-3p, miR-
590-3p, miR-93–3p, and miR-133a-3p; p value range, .004–.039),
and two were downregulated (miR-29b-3p and miR-31-5p;
p values .097 and .099, respectively) (Fig. 3A–G).
Ongoing osteoporosismedication at the timeof the studyhadno
systematic effect on miRNA values (Fig. 3A–G). To evaluate gender
differences in miRNA levels, we evaluated the same 13 miRNAs in
female and male subjects separately. When comparing miRNA con-
centrations between mutation-positive and mutation-negative
females alone, the statistical significance persisted for expression
of nine of the 13 miRNAs (miR-93-3p, miR-532-3p, miR-133a-3p,
miR-301b-3p, miR-590-3p, miR-23b-3p, miR-128-3p, miR-20b-3p,
and miR-31-5p; p value range, .007–.042). None of the 13 miRNAs
reached a statistical significance level in males (p value range,
.183–.840).
In silico prediction and in vitro confirmation of miRNA
targets
First, we set out to identify putative miRNA binding sites in the
human PLS3 3’-UTR region for these 13 specific miRNAs, with
Fig 4 Luciferase reporter assay confirming posttranscriptional regulation of PLS3 bymiR-181c-5p. The experiment used a dual-luciferase reporter plasmid
containing PLS3 3’-UTR sequence (including the putative miR-181c-5p binding site). Plasmids were transfected into HEK293 cells at two different concen-
trations (0.25 μg and 0.1 μg), either alone (WT), in combination with a negative control miRNA (WT+scr), or in combination with miR-181c-5p (WT+181c).
One-way ANOVA analysis with Tukey’s post hoc comparison was used.
Table 3 Previously Reported Data on the Role in Bone Metabolism of the Seven Discriminative miRNAs in PLS3 Mutation-Positive
Subjects
miRNA-ID
Regulation
in MP
subjects Role in bone metabolism Target proteins in bone References
miR-93-3p Down Negative regulator of osteogenic differentiation; upregulated in
low BMD in postmenopausal osteoporosis
RUNX2 51,52
miR-532-3p Down Upregulated in patients with vertebral fractures or low BMD,
correlated with serum ALP
– 53
miR-133a-3p Down Downregulated or upregulated in mandible and femur of
ovariectomized mice, respectively; upregulated in low BMD in
postmenopausal osteoporosis; inhibits bone metastasis in
prostate cancer
TGF-β, WNT pathway,
RUNX2, CXCL11, CXCR3,
SLC29A1, PI3K/AKT
pathway
52–56
miR-301b-3p Up Upregulated in bone of placebo-treated ovariectomized rats,
and downregulated following PTH treatment
– 30
miR-181c-5p Up Partakes in microgravity-induced abnormal osteoblast
proliferation; regulated in postmenopausal osteoporotic
patients
Cyclin B1 15,36
miR-203a-3p Up Regulates osteoblast differentiation; inhibits osteogenesis
diabetic rats’ jaw bones; upregulated in femoral heads and
serum of ovariectomized rats, downregulation in response to
anabolic treatment
DLX5, RUNX2, SMAD1 37,38,40,50
miR-590-3p Down Decreased expression in osteosarcoma SOX9 57
miRNAs with overall p value < 0.05 are shown in bold.
miRNA/miR = microRNA; MP = mutation-positive.
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binding sites conserved across mammalian species using TargetS-
can v7.2.(25) From the list of top 20 regulated candidates, we iden-
tified binding sites in the human PLS3 gene for three miRNAs: miR-
203a-3p, miR-181c-5p, and miR-218-5p. Of these, miR-218-5p had
been experimentally validated by high-throughput sequencing of
RNA isolated by crosslinking immunoprecipitation (HITS-CLIP),(26)
and for miR-181c-5p and miR-203a-3p, bioinformatic predictions
suggest interaction with PLS3. Therefore, a luciferase reporter con-
struct containing the PLS3 3’-UTR was generated and tested for
interaction with both miRNAs. Results for miR-181c-5p showed a
clear interaction with PLS3 3’-UTR based on a decrease in luciferase
signal compared to the negative control (Fig. 4), while the results
for miR-203a-3p were inconclusive (data not shown).
To complement this analysis, mRNA targets of all seven statis-
tically significantly upregulated or downregulated miRNAs in
serum of mutation-positive subjects were derived from miRWalk
3.0. In total, 244 genes showed a putative interaction with one or
more of these miRNAs. Of these genes, a strong enrichment in
the TGF-beta signaling pathway (Kyoto Encyclopedia of Genes
and Genomes [KEGG] hsa04350, six genes, adjusted p value
.025) and WNT signaling pathway (KEGG hsa04310, six genes,
adjusted p value .092) was observed (Table 4).
Discussion
This study reports for the first time on circulating levels of miR-
NAs in relation to defective PLS3 function. Our cohort comprised
15 subjects with different PLS3 loss-of-function mutations lead-
ing to low BMD and frequent fragility fractures. The affected
males presented with a more severe skeletal phenotype com-
pared with the females owing to the X chromosomal inheritance
of PLS3. We screened a custom-designed panel consisting of
192 miRNAs and compared the results with congruent findings
in 14 mutation-negative subjects from the same families. Our
results reveal a unique profile of seven different miRNAs that sta-
tistically significantly differ between the mutation-positive and
mutation-negative subjects. Surprisingly, the difference to con-
trols was even greater in the PLS3 mutation-positive females
than in the mutation-positive males. All seven most significantly
regulated miRNAs in the mutation-positive subjects have been
previously related to bonemetabolism, but their association with
PLS3 has not been reported.
Recently, miRNAs have attained much attention as potential
markers for chronic diseases and targets for novel therapeutics.
Previous reports have shown that miRNA expression levels corre-
late with BMD and fracture risk, relate to disease status in post-
menopausal osteoporotic patients,(13,15) and can differentiate
between patient cohorts in several other chronic diseases.(14,27)
We have also shown that miRNA profiles can differentiate
mutation-positive subjects in another monogenic skeletal dis-
ease; we found altered expression levels and a unique profile
of eight differentially expressed miRNAs in a cohort of 17 WNT1
mutation-positive subjects with autosomal dominant WNT1
osteoporosis.(8) However, serum miRNA concentrations in other
monogenic disorders have hardly been explored.
Although the number of diagnosed PLS3 mutation-positive
patients has increased and the skeletal characteristics are well
documented, the exact molecular mechanisms and signaling cas-
cades in which PLS3 partakes in bone metabolism continue to be
clarified. Of the seven discriminating miRNAs in our study, six have
been previously reported to influence bone metabolism in
humans (Table 3) and their reported roles parallel their upregula-
tion or downregulation in the presence of mutated PLS3. For
miR-301b-3p this is the first report indicating it serves a role in skel-
etal homeostasis in humans. Previously it hasmainly been linked to
hypoxic events such as hypoxia-induced carcinogenesis in prostate
and other cancers(28) and pulmonary vascular proliferation and
vasoconstriction in pulmonary hypertension.(29) However, recently
it was reported to be linked to bonemetabolism in ovariectomized
rats,(30) and TargetScan also predicts it to interact directly with sev-
eral bone-related proteins, such asWNT1, LRP6, and PTEN. Further-
more, miR-301b belongs to themiR-130 gene family together with
miR-130b, miR-301a, and miR-130a,(31) which in turn have been
reported to partake in osteogenesis and chondrogenesis.(32,33)
Last, Liu and colleagues(34) have reported that expression of miR-
301b-3p in bone marrow correlates with adipogenic potential of
mesenchymal stem cells (MSCs).
Three miRNAs—miR-181c-5p, miR-203a-3p, and miR-
218-5p—are predicted or experimentally validated to interact
with or bind to PLS3. First, miR-181c-5p, which relates to post-
menopausal osteoporosis and fracture risk in diabetic
patients,(13,15,35) inhibits osteoblast proliferation in simulated
microgravity-settings through interactions with cyclin B1.(36)
Here, we could experimentally validate the interaction between
miR-181c-5p and PLS3. Second, miR-203a-3p is reported to regu-
late osteoblast differentiation through repressing DLX5 and
RUNX2 in traumatic heterotopic ossification and in bone lesions
of metastatic breast cancer,(37–39) and to inhibit osteogenesis in
diabetic rats’ jaw bones.(40) The role of miR-203a-3p in bone
metabolism and its inhibitory functions on bone formation are
quite well established and in the light of our results, it could be
hypothesized that some of its regulatory actions are transmitted
through interactions with PLS3. Last, miR-218-5p has been stated
to promote osteogenic differentiation of MSCs in mice(41) and
increase bone formation by targeting WNT pathway
inhibitors,(42) all the while also negatively regulating osteoclasto-
genesis through RANKL, Mmp9, and NF-κB.(43,44)
Table 4 mRNA Targets for the Top Seven Significantly Upregulated or Downregulated SerummiRNAs (p value <.05) in 15 PLS3Mutation-
Positive Subjects
KEGG pathway ID KEGG pathway Genes (n) p p (BH-adjusted)
hsa04350 TGF-beta signaling pathway 6 .0014 .028
hsa04360 Axon guidance 8 .0037 .037
hsa04150 mTOR signaling pathway 6 .0198 .092
hsa05205 Proteoglycans in cancer 7 .0232 .092
hsa04310 Wnt signaling pathway 6 .0172 .092
hsa04270 Vascular smooth muscle contraction 5 .0276 .092
mRNA targets were derived from miRWalk 3.0.
BH = Benjamini-Hochberg; hsa = human microRNA; KEGG = Kyoto Encyclopedia of Genes and Genomes.
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Of note, we have recently published findings of elevated serum
Dickkopf-1 (DKK1; dickkopf WNT signaling pathway inhibitor 1)
concentrations in these same PLS3 mutation-positive subjects.(45)
DKK1 is an osteocyte-derived inhibitor of the WNT pathway in
bone. It downregulates WNT signaling by binding to LRP5,(46) pre-
venting binding of a WNT ligand. Although the mechanisms
behind themolecular interactions between PLS3 and DKK1 are still
unknown, interestingly two of our upregulated miRNAs of interest
also target DKK1. miR-203 promotes osteogenic differentiation of
MSCs by inhibiting and degrading DKK1(47) and, similarly, miR-
218-5p promotes osteogenic differentiation of synovium-derived
fibroblast-like cells in rheumatoid arthritis by suppressing
DKK1.(48) Further, we noticed enrichment in the WNT pathway
when looking at mRNA targets for the seven top miRNAs
(Table 4). Interestingly, four of the significantly expressed miRNAs
in this study (miR-31-5p, miR-200b-3p, miR-423–3p, miR-128-3p)
also showed differential expression in our previous study on miR-
NAs in WNT1 osteoporosis,(8) with p values <.1 for each miRNA in
both cohorts. The molecular associations between these miRNAs
and PLS3 still need further consideration.
We noticed a difference between genders, with the mutation-
positive females having more significant changes than the
mutation-positive males in comparison to corresponding
mutation-negative subjects. Due to the X-linked inheritance pat-
tern, PLS3 osteoporosis predominantly affects males whereas
female carriers exhibit a much milder phenotype.(18,19) There-
fore, this counterintuitive finding is interesting yet unclear. Some
of the differences between mutation-positive and mutation-
negative males could be downplayed by their relatively small
cohort size compared to females (5 versus 10). However, prior
studies congruently report gender differences in PLS3 function.
For example, PLS3 has been reported to be a gender-specific
modifier in spinal muscular atrophy.(49,50) We also found a similar
gender-dependent difference in circulating DKK1 concentra-
tions, PLS3 mutation-positive females showing significantly ele-
vated and greater concentrations than males when compared
with mutation-negative female controls.(45)
Prior or ongoing osteoporosis medication could potentially
introduce bias on miRNA expression levels.(30) Our cohort
included altogether six subjects with previous, and three sub-
jects with ongoing osteoporosis treatment at the time of the
study. However, separate analysis indicated no relationship
between treatment and miRNA levels. This is similar to our previ-
ous observation in miRNAs in WNT1 osteoporosis.(8)
We also acknowledge other limitations our study may have,
mainly concerning the relatively small cohort size, heterogene-
ity of PLS3 mutations, and the cross-sectional nature of the
study. A greater number of study subjects with similar muta-
tions, and exclusion of mutation-negative subjects with a posi-
tive fracture history or osteoporosis would perhaps better
reflect the true difference in miRNA expression levels in PLS3
osteoporosis and solidify the observed gender differences. A
longitudinal study setting would allow to evaluate the changes
in miRNA levels with respect to disease progression or treat-
ment response and assess their potential as biomarkers. Also,
although relatively inclusive, our panel consisted of only
192 miRNA species, which could count out some important
and bone-specific or relevantly expressed miRNAs. Because of
the exploratory nature of this study we purposely decided to
apply relaxed statistical cutoffs (ie, no adjustment for multiple
testing), which could have resulted in a higher false-positive
rate, and, thus, the results will require independent confirma-
tion. Further, we recognize some potential confounding factors
that could introduce bias, such as other medications or illnesses.
The medication intakes, however, were similar in both groups
and the two groups were otherwise highly alike with regard to
age, gender, and family and genetic background. Furthermore,
given the rarity of PLS3 osteoporosis, the scarce number of
PLS3 mutation-positive subjects, and the unknown pathome-
chanisms behind PLS3-related bone disease, we consider our
study topic relevant and current, and the findings scientifically
novel and greatly valuable.
In conclusion, our study identified a specific pattern of circu-
lating miRNAs in PLS3mutation-positive subjects. These findings
imply that there is possible crosstalk between PLS3 and specific
miRNAs in bone metabolism and that the identified miRNAs
could contribute to the skeletal pathology in PLS3 osteoporosis.
Importantly, several of these miRNAs show association with the
WNT pathway, an observationwhichmay have relevance in under-
standing the pathomechanisms underlying PLS3 osteoporosis and
in advancing patient management. Because conventional meta-
bolic bone markers are normal in PLS3mutation-positive subjects,
our findings could provide novel avenues for utilizing miRNAs as
biomarkers in diagnosing and monitoring patients. These miRNAs
may also be explored as therapeutic targets to improve skeletal
health by influencing PLS3 signaling.
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